Benitec delays IND filing for HIV/AIDS therapeutic pending resolution of manufacturing result
Sara M. Cunningham, Chief Executive Officer of Benitec, stated "We are working closely with the manufacturing team to resolve this unanticipated result and will move forward as quickly as possible with the IND filing. Although the result is unrelated to the safety or efficacy of the drug, we will not file the IND until we are certain that all components of the clinical materials are fully and properly characterized and pass our stringent manufacturing criteria."
Most read news
Other news from the department research and development
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.